Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 606 | 150 | 449 |
| Samples | 227 | 59 | 164 |
| Peptides | 124 | 39 | 98 |
Function
VCX · Variable charge X-linked
This gene belongs to the VCX/Y gene family, which has multiple members on both X and Y chromosomes, and all are expressed exclusively in male germ cells. The X-linked members are clustered on chromosome Xp22 and Y-linked members are two identical copies of the gene within a palindromic region on Yq11. The family members share a high degree of sequence identity, with the exception that a 30-bp unit is tandemly repeated in X-linked members but occurs only once in Y-linked members. The VCX gene cluster is polymorphic in terms of copy number; different individuals may have a different number of VCX genes. VCX/Y genes encode small and highly charged proteins of unknown function. The presence of a putative bipartite nuclear localization signal suggests that VCX/Y members are nuclear proteins. This gene contains 10 repeats of the 30-bp unit. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000381059 | Q9H320 | 241 | 114 |
| ENST00000341408 | J3KNW2* | 223 | 110 |
| ENST00000620630 | A0A087X1S4* | 130 | 67 |
| ENST00000688183 | Q9H320 | 12 | 9 |
Gene Properties
Recurrent Mutations
All 119 amino-acid changes on canonical ENST00000381059 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in VCX · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in VCX – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Non-Small Cell Lung Carcinoma | 20/304 7% | 10/1390 1% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 7/810 1% |
| Melanoma | 5/210 2% | 16/1899 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Other Solid Cancers | 5/94 5% | 10/1515 1% |
| Endometrial Carcinoma | 0/42 0% | 6/612 1% |
| Esophageal Carcinoma | 1/23 4% | 6/769 1% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Head and Neck Carcinoma | 3/85 4% | 9/1574 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 4/752 1% |
| Gastric Carcinoma | 1/74 1% | 11/1809 1% |
| Colorectal Carcinoma | 1/143 1% | 19/3239 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 9/1592 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Other Blood Cancers | 0/61 0% | 11/2725 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Breast Carcinoma | 1/144 1% | 9/3264 0% |
| Pancreatic Carcinoma | 0/89 0% | 5/1611 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 3/2640 0% |
| Glioma | 1/52 2% | 2/2127 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 3/2534 0% |
Mutation Distribution
Where VCX is mutated · all tissues, split by cell line vs tissue
How many mutations in VCX were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 24 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 606 mutations in VCX
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|